Shilpa Medicare的NAFLD药物(NorUDDCA)成功完成了第三阶段试验,激增占11%。 Shilpa Medicare's NAFLD drug, NorUDCA, completes successful Phase 3 trials and surges shares 11%.

Shilpa Medicare的股份在成功完成了对NorUDDCANAFLD药物的第三阶段试验后, 将11%的股份飙升到创纪录的高点。 Shilpa Medicare's shares soared 11% to a record high after successfully completing Phase 3 trials for its NAFLD drug, NorUDCA. 该药物旨在治疗非酒精脂肪肝病,在试验期间显示出积极的成果,没有严重的副作用。 The drug, designed to treat Nonalcoholic Fatty Liver Disease, demonstrated positive outcomes during trials with no serious side effects. Shilpa Medicare计划向CDSCO提交第三阶段调查结果,供其在印度进行销售授权,这有可能使NAFLD治疗发生革命性变化。 Shilpa Medicare plans to submit Phase 3 findings to CDSCO for marketing authorization in India, potentially revolutionizing NAFLD treatment.